A new drug industry-patient advocacy group consortium aims to take biopharma-patient collaboration to the next level by figuring out how these partnerships can improve the effectiveness and efficiency of drug development.
“There's a lot of effort and a lot of resources being put into collaborating, making sure that the patient voice, each representative is deeply embedded in drug development
Key Takeaways
-
New consortium of drug industry, patient advocacy groups wants to make these growing partnerships more efficient and effective to ensure they actually speed drugs to market.
-
PALADIN spent its first year standardizing processes for partnerships
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?